Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0725

0.0%

9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jack Russell who wrote (13057)	9/30/2015 9:32:01 AM
From: Jack Russell	Read Replies (1) of 13111

Provectus Biopharmaceuticals Reports Publication of Review Paper on PV-10 Tumor Ablation and Immune Stimulation (Ref: Business Wire) September 29th, 2015 Journal of Clinical and Cellular Immunology Publishes Paper Authored by Researchers at University of Illinois at Chicago KNOXVILLE, Tenn.--( BUSINESS WIRE)-- Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, firstwordpharma.com, a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or the "Company"), today reported that the Journal of Clinical and Cellular Immunology has published a paper titled, "The Potential of Intralesional Rose Bengal to Stimulate T-Cell Mediated Anti-Tumor Responses." The paper can be found online at firstwordpharma.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next